[stock_market_widget type=”card” template=”basic2″ assets=”LXRX” realtime=”true” api=”yahoo-finance”]
Drug trials tend to move slowly, so the moments when they hit a clear mark are worth noticing. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a biopharmaceutical company based in The Woodlands, Texas, told investors it had finished enrolling patients in a large late-stage study of its heart medicine, and that the study had drawn more people than planned. For a company of its size, filling a trial on schedule is not a small thing, and it clears the way for a set of results that could shape the next year or two.
The study, called SONATA-HCM, is testing a drug named sotagliflozin in people with hypertrophic cardiomyopathy, a condition in which the heart muscle grows abnormally thick and has a harder time pumping blood. Lexicon said the trial passed its target of 500 patients, drawing volunteers from more than 130 sites across 20 countries, with the largest share having the non-obstructive form of the disease. The main goal is to measure whether patients feel better, and the company expects to report the first results in the first quarter of 2027.
The reason this matters goes beyond one trial reaching a milestone. Sotagliflozin is already sold in the U.S. as INPEFA, where it is approved to treat heart failure, so a positive readout in hypertrophic cardiomyopathy would give an existing product a second reason to exist and a new group of patients to reach. Getting there still depends on the data, which remains a genuine unknown until it arrives. Completing enrollment on time simply means the clock to that answer is now running.
The financial picture behind all this is the familiar one for a company still spending to build its pipeline. Lexicon reported a net loss of $31.8 million, or $0.07 per share, for the second quarter of 2026, with product revenue of roughly $0.7 million from INPEFA. It held $190.6 million in cash and investments at the end of June, helped by a stock sale earlier in the year, and in May it signed a new loan facility of up to $100 million with Hercules Capital, using part of it to pay off an older loan.
Two other efforts sit alongside the heart program. The first is ZYNQUISTA, the company’s candidate for type 1 diabetes, aimed at adults who today have no approved options beyond insulin. Lexicon plans to resubmit its application to the U.S. Food and Drug Administration in the fourth quarter of 2026, drawing on safety data from an independent study running in Denmark. A resubmission is not an approval, but it would put the drug back in front of regulators after an earlier setback.
The second is an obesity drug called LX9851, which Lexicon has licensed to Novo Nordisk A/S (NYSE: NVO), the Danish maker of Ozempic and Wegovy. Novo Nordisk began an early-stage human study of the compound in March and is running it. Under the agreement, Lexicon has received an upfront payment and development payments, and it could earn further milestone payments reaching as much as $1 billion in total, plus royalties on any future sales. Separately, Lexicon has licensed sotagliflozin outside the U.S. and Europe to Viatris Inc. (NASDAQ: VTRS), which is pursuing approvals in a range of markets.
The takeaway is that Lexicon has turned a plan into a finished step, and its story now hinges on events with firm dates: heart trial results early in 2027, a diabetes filing late in 2026, and an obesity program moving through Novo Nordisk’s hands. Each carries real risk, since trials can fail and regulators can say no. What changed today is that one of those uncertainties, whether the company could gather enough patients in time, is no longer in question.
